冠状动脉高度钙化病变修饰对冠状动脉微循环的影响
This is a prospective, single-center, three-arm study to evaluate the impact of severely calcified coronary lesions treatment on microvascular circulation. We will enroll 30 conveniently sampled subjects assigned to one of three therapeutical methods lithotripsy, super-high pressure balloon, and orbital atherectomy prior to implantation of drug-eluting stents (DES).
研究概览
地位
详细说明
This prospective, non-randomized, single-center study includes subjects who meet all of the inclusion and none of the exclusion criteria and sign the ICF. 30 patients with severe coronary stenosis will be enrolled. The severity will be assessed by Optical Coherence Tomography (OCT) based on the degree of calcification in the coronary lesion as defined by this protocol. Subjects will be assigned to one of three arms (lithotripsy, super-high pressure balloon or orbital atherectomy) followed by an implantation of drug-eluting stents (DES). The aposition and expansion of DES will be evaluated using OCT . Patients will be followed through discharge, 30 days and 12 months.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Katowice、波兰、40-081
- Upper Silesian Medical Centre
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subjects with native coronary artery disease (including stable or unstable angina and NSTEMI) suitable for PCI.
- The lesion must be crossable with the study guide wire.
- The target vessel reference diameter must be ≥ 2.5mm and ≤ 4.0 mm.
- The target lesion must have evidence of severe calcium deposit at the lesion site based on the protocol criterion.
- Subject or legally authorized representative, signs a written Informed Consent form to participate in the study, prior to any study-mandated procedures.
- Male or female, age above or equal to 18 years at the time of signing informed consent.
Further inclusion criteria may apply
Exclusion Criteria:
- Inability to understand the study or a history of non-compliance with medical advice.
- Unwilling or unable to sign the Informed Consent Form (ICF).
- History of any cognitive or mental health status that would interfere with trial participation.
- Male or female, age under 18 years at the time of signing informed consent.
- Female subjects who are pregnant or planning to become pregnant within the study period.
- Subject has a known sensitivity to contrast media, which cannot be adequately pre-medicated.
- Subject has evidence of an active infection on the day of the procedure requiring oral or intravenous antibiotics.
- Limited long term prognosis due to other conditions.
- Subjects in cardiogenic shock or with decompensated heart failure (NYHA class IV).
- Subject diagnosed with chronic kidney disease stage 4 or greater (eGFR <30).
- Most recent left ventricular ejection fraction ≤ 20%.
- Subject is an acceptable candidate for coronary artery bypass surgery.
- The target vessel reference diameter is under 2.0 mm.
- Target lesion is located in or supplied by an arterial or venous bypass graft.
- The target vessel has angiographically visible or suspected thrombus.
- The target lesion is in an in-stent restenosis.
- Subject has received a heart transplant.
- Subject has major valve disease and underwent intervention within 30 days prior to randomization.
Further exclusion criteria may apply
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：非随机化
- 介入模型：并行分配
- 屏蔽：单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：High-pressure non-compliant balloon
The SIS Medical OPN NC® super high-pressure coronary balloon will be used for balloon angioplasty vessel preparation prior to implantation of a drug-eluting stent. |
Calcified lesion preparation using high-pressure non-compliant balloon before implantation of a drug-eluting stent Optical coherence tomography assessment of coronary arteries. A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function. |
|
实验性的：Orbital atherectomy
The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent. |
Optical coherence tomography assessment of coronary arteries. A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function. Calcified lesion preparation using orbital atherectomy before implantation of a drug-eluting stent |
|
实验性的：Lithotripsy
The Shockwave® Medical system will be used for intravascular lithotripsy (IVL) vessel preparation prior to implantation of a drug-eluting stent. |
Optical coherence tomography assessment of coronary arteries. A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function. Calcified lesion preparation using lithotripsy before implantation of a drug-eluting stent |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Coronary Flow Reserve (CFR)
大体时间：Intraprocedural
|
Determination of a difference between Coronary Flow Reserve (CFR) at the beginning and at the end of the procedure using CoroFlow™ Cardiovascular System. |
Intraprocedural
|
|
Index of Microcirculatory Resistance (IMR)
大体时间：Intraprocedural
|
Determination of a difference between Index of Microcirculatory Resistance (IMR) at the beginning and at the end of the procedure using CoroFlow™ Cardiovascular System. |
Intraprocedural
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Stent expansion
大体时间：Intraprocedural
|
Stent expansion (%) evaluated by optical coherence tomography. |
Intraprocedural
|
|
Acceptable stent expansion
大体时间：Intraprocedural
|
Acceptable stent expansion (cut-off value defined as >80%) evaluated by optical coherence tomography. |
Intraprocedural
|
|
Optimal stent expansion
大体时间：Intraprocedural
|
Optimal stent expansion (cut-off value defined as >90%) evaluated by optical coherence tomography. |
Intraprocedural
|
|
Minimal lumen diameter (MLD) difference
大体时间：Intraprocedural
|
Determination of a difference between quantitative OCT measured minimal lumen diameter (MLD) at the beginning and at the end of the procedure. |
Intraprocedural
|
|
Procedural Success
大体时间：Up to 3 years
|
Procedural success - defined as successful stent delivery and angiographic in-vessel residual stenosis <30%, and with the absence of any of the following: stent loss, coronary artery dissection, coronary artery perforation, PCI no reflow phenomenon or MACCE (defined as a composite of cardiovascular death, myocardial infarction at the targeted vessel, targeted coronary vessel revascularization (PCI or CABG), TIA or stroke). |
Up to 3 years
|
|
Strategy Success
大体时间：Intraprocedural
|
Strategy success - defined as procedural success without crossover to alternative treatment. |
Intraprocedural
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The proportion of subjects that experience Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
大体时间：Up to 3 years
|
30-day and 1 year MACCE defined as a composite of cardiovascular death, myocardial infarction at the targeted vessel, targeted coronary vessel revascularization (PCI or CABG), TIA or stroke. |
Up to 3 years
|
|
The proportion of subjects that experience Target Vessel Revascularization (TVR)
大体时间：Up to 3 years
|
30-day and 1 year Target Vessel Revascularization (TVR) - defined as any repeat revascularization at the target vessel (inclusive of the target lesion) and target vessel collaterals after the completion of the procedure. |
Up to 3 years
|
|
The proportion of subjects that experience Target Lesion Revascularization (TLR)
大体时间：Up to 3 years
|
30-day and 1 year Target Lesion Revascularization (TLR) - defined as repeat intervention PCI or surgery within the index procedure stent or 5mm proximal or distal to the stent. |
Up to 3 years
|
|
Myocardial infarction (MI) rate at 30-day and 1 year
大体时间：Up to 3 years
|
The proportion of subjects that experience a Myocardial Infarction (MI) at 30-day and 1 year. |
Up to 3 years
|
合作者和调查者
调查人员
- 首席研究员：Paweł Gąsior, MD, PhD、Division of Cardiology and Structural Heart Diseases, Medical University of Silesia
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- BNW/NWN/0052/KB1/4/24
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.